

## Resignation of Statutory Auditor

Milan (Italy), 13 April 2009 - MolMed S.p.A. (Milan:MLM), announces that Mr. Oliviero Eric Cimaz today communicated to the Company his resignation from the position of member of MolMed's Board of Statutory Auditors for personal reasons.

MolMed's Shareholders' Meeting - convened on 26 April 2010 in first call, and on 30 April 2010 in second call - will, among other things, resolve upon the appointment of the members of the Board of Statutory Auditors, as foreseen by point 3 of the Shareholders' Meeting agenda in its Ordinary Part. Until then Mr. Cimaz, whose resignation has immediate effect, will be replaced by the Substitute Statutory Auditor Mr. Antonio Marchesi.

---

*This press release is written in compliance with public disclosure obligations established by Consob (the Italian securities & exchange commission) resolution no. 11971 of 14.5.1999, as subsequently amended.*

### About MolMed

MolMed S.p.A. is a biotechnology company focused on research, development and clinical validation of novel antitumour therapies. MolMed's pipeline includes two novel therapeutics in clinical development: TK, a cell-based therapy enabling bone marrow transplants from partially compatible donors, in Phase III in high-risk acute leukaemias; NGR-hTNF, a novel vascular targeting agent (VTA), in Phase III in malignant pleural mesothelioma and in Phase II in five other indications: colorectal, lung (small-cell and non-small-cell), liver and ovarian cancer. MolMed is headquartered at the San Raffaele Biomedical Science Park in Milan, Italy. The company's shares (Milan:MLM) are listed on the Milan Stock Exchange, at the Standard segment (class I) of the MTA managed by Borsa Italiana.

### For further information, please contact:

Holger Neecke  
*Director Business Development & IR*  
MolMed S.p.A.  
phone: +39 02 21277.205  
fax: +39 02 21277.325  
e-mail: investor.relations@molmed.com

Elena Lungagnani  
*Communication Manager*  
MolMed S.p.A.  
phone: +39 02 21277.207  
fax: +39 02 21277.325  
e-mail: media.relations@molmed.com